Medi-Tate Overview
Medi-Tate develops new solutions for treating diseases of the urethra and prostate. Its solutions are designed to reduce associated symptoms and significantly improve patients' quality of life. The Medi-Tate device offers patients relief from the symptoms of benign prostate hyperplasia (BPH). The device is placed in the prostatic urethra for five days. During this time, it pushes obstructive tissue to the side, reshaping the prostate to create a long-term therapeutic effect. The device can be deployed in any clinical setting with standard rigid cystoscopy equipment. The deployment procedure is intuitive and does not require a postprocedural catheter. Once the device is deployed, the patient is free to return to normal activities immediately. Medi-Tate's iTind system for the treatment of BPH is CE marked and available for sale in the European Union, Canada, Hong Kong, and Israel. In April 2020, the company received an FDA De Novo classification for its iTind system.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
First BPH Treatment Procedures Performed in Canada with Minimally Invasive iTind Device
Olympus has announced the first commercial treatment of Benign Prostatic Hyperplasia (BPH) in Canada using the minimally invasive iTind procedure. Dr. Dean Elterman, a urologist, performed the procedure, offering a treatment option beyond medication, surgery, or permanent implants. BPH affects a significant percentage of men, and the iTind procedure provides quick and effective relief from symptoms. The procedure takes a week and involves reshaping the prostate using a temporary implant. Most men can go home without the need for a catheter after the device is removed. The iTind procedure can be offered by physicians in various settings, including smaller, rural facilities. Olympus is a leading medical technology company focused on creating customer-driven solutions for the medical industry.
Customers
growth-positive
Study Results Show Long-term Efficacy of iTind Procedure
Olympus announced the summary results of a follow-up study on the durability of the iTind procedure for treating lower urinary tract symptoms caused by BPH. The study showed long-term efficacy and durability of up to 6.6 years. Two out of 50 patients required subsequent surgical intervention, but no complications were reported. The results demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms. The study results were highly anticipated by urologists and generated high interest in the iTind device at the American Urological Association Annual Meeting.
Customers
growth-positive
Olympus Selected To Exhibit iTind Device For BPH Treatment At Vizient Innovative Technology Exchange
Olympus will exhibit its iTind device for relief of enlarged prostate symptoms at the Vizient Innovative Technology Exchange. The device offers a minimally invasive treatment option that rapidly relieves symptoms while preserving sexual function. The annual exchange allows suppliers to demonstrate their technologies to supply chain and clinical leaders from Vizients member hospitals. The iTind device reshapes the prostate using temporary implants, creating channels for urine flow. It avoids complications associated with drugs, surgery, or permanent implants. Olympus aims to improve clinical outcomes, reduce costs, and enhance patients quality of life. The company is excited to showcase the positive outcomes of the iTind device at the exchange.
PartnersCustomers
growth-positive
Olympus buys Israeli co Medi-Tate for $300m
Japanese medical device company Olympus Corp. is acquiring Israeli medical device company Medi-Tate at a company valuation of $300 million. Medi-Tate develops minimally-invasive treatments for the lower urinary tract. The acquisition represents a profitable exit for Medi-Tates shareholders, including Olympus. Following the acquisition, Medi-Tate will become Olympus R&D Center in Israel. Olympus is traded on the Tokyo Stock Exchange with a market cap of $27 billion. Cooperation between Olympus and Medi-Tate began in 2018 when Olympus received distribution rights to Medi-Tates products. Medi-Tates flagship product is iTind, a device for treating benign prostate hyperplasia. BPH affects almost 50% of men over 50 and is a common reason for lower urinary tract symptoms. The cost of treating BPH in the US is estimated at $10 billion per year.
Acquisition
growth-positive
iTind for Benign Prostatic Hyperplasia Gets FDA Green Light - TMG Pulse
Medi-Tates iTind System, a temporary implantable nitinol device for the relief of lower urinary tract symptoms, has received investment from Olympus, who also has the option to purchase the company. The iTind System offers rapid symptom relief, preserves sexual function, and is a straightforward and easy ambulatory procedure. It does not require a permanent implant or a catheter, and has minimal downtime. The FDA has also provided related study results for the device. The article does not mention any specific customers, acquisition or investment amounts, or layoffs. The date of the event described in the article is not provided.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $30M |
| Last funding | $20M |
| Stage | Acquired |
| Rounds | 3 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.itind.com/ |
Photos & Videos
3 item(s)
